Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain

Summary

This study is being done to test the safety and efficacy of the study drug LY3556050 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.

Timeline

Start

2021-05-06

Primary completion

2022-06-13

Completion

2022-06-13

Outcome

Met primary endpoint

Stopped (Enrollment): “The trial was slow to enroll, and the sponsor made a business decision to terminate the trial earlier than planned.”

registry analysis (superiority test); 600 mg LY3556050 vs Placebo; Posterior Mean Difference -1.56 (95% CI -2.76 to -0.38) NCT04707157 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY3556050	Unknown	600 mg	Oral

Indications